Loading insider details...
Beta
Latest Form 4 (Jun 8, 2026): Sale of 2,625 KROS shares, $28.2K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Keros Therapeutics, Inc. (KROS) | Sale | 2,625 | $28.2K |
| Jun 5, 2026 | Keros Therapeutics, Inc. (KROS) | Grant/Award | 7,142 | n/a |
| Jun 6, 2025 | Keros Therapeutics, Inc. (KROS) | Grant/Award | 5,250 | n/a |
| Jun 3, 2024 | Keros Therapeutics, Inc. (KROS) | Grant/Award | 10,000 | n/a |
| Apr 5, 2024 | Kinnate Biopharma Inc. (KNTE) | Disposition to Issuer | 2,186 | n/a |
| Jun 8, 2023 | Keros Therapeutics, Inc. (KROS) | Grant/Award | 10,000 | n/a |
| Jun 3, 2022 | Keros Therapeutics, Inc. (KROS) | Grant/Award | 8,293 | n/a |
| Jun 3, 2021 | Keros Therapeutics, Inc. (KROS) | Grant/Award | 8,293 | n/a |
| May 29, 2020 | Keros Therapeutics, Inc. (KROS) | Grant/Award | 8,500 | n/a |